News and Features
Adult and Adolescent ARV Guideline Panel Issues Statement on Bictegravir
The Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV panel issued a statement on the use of bictegravir (BIC). A summary of the statement is below.
BIC/TAF/FTC is an effective and well-tolerated INSTI-based regimen for initial therapy in adults with HIV, with efficacy that is noninferior to DTG/ABC/3TC and DTG plus TAF/FTC for up to 48 weeks. On the basis of these clinical trial results, the Panel classifies BIC/TAF/FTC as one of the Recommended Initial Regimens for Most Adults with HIV (AI).
Perinatal Guideline Panel Adds Guidance on Breastfeeding
Guidance for Counseling and Managing Women Living with HIV in the United States Who Desire to Breastfeed was added to the Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States.
While the Panel does not recommend breastfeeding for women with HIV, this section is intended to provide tools to help providers counsel women living with HIV on the potential risks associated with breastfeeding and to provide a harm-reduction approach for women who choose to breastfeed despite intensive counseling. This section is not intended to be an endorsement of breastfeeding, nor is it a recommendation to breastfeed for women living with HIV in the United States.